We develop curated libraries of drug-like scaffolds designed specifically for screening by external partners (academic labs, biotech firms, contract research organizations). The library will combine diversity, drug-likeness, synthetic tractability, scaffold novelty, and focused subsets, enabling customers to (i) screen broadly against novel targets, (ii) quickly cherry-pick candidate compounds, and (iii) accelerate hit identification with lower cost and risk.
An Overview
Build a searchable library of plant molecules—most never studied before
Use AI fluent in chemistry to scale analysis from one molecule to 10,000 at a time.
Run a fully automated lab to screen molecules and determine their therapeutic properties at high throughput
1. Core Diversity Set
• ~50,000–200,000 compounds.
• Broad chemical space coverage.
• Drug-like, 3D-supporting, sp³-rich, scaffold varied.
2. Functional / Targeted Subsets
• Kinase inhibitors, GPCR binders, ion channel modulators, PPI inhibitors, etc.
• Use pharmacophore and similarity modeling to known ligands to populate.
3. Lead-Like / Fragment Subset
• Smaller size, simpler molecules (lower MW, fewer rotatable bonds) suitable for fragment-based screening or hit expansion.
• “Rule of Three” compliance etc
Commercial Utility & Value Proposition
Why such a library has commercial appeal; what problems it solves for potential customers:
• Faster hit discovery — virtual screening against a well-curated library reduces wasted efforts on compounds that fail early (poor properties, reactive, insoluble).
• Higher hit quality — more likely to find hits with both potency and acceptable ADMET profile, reducing costs downstream.
• IP benefit — scaffolds selected with novelty in mind allow customers to generate leads that are patentable.
• Cost-efficiency — save customers’ time and resources: fewer physical compounds to screen after virtual enrichment; less iteration of chemistry.
• Flexibility & scaling — customers may begin with virtual sets, cherry-pick for physical screening, then order or synthesize. The library supports small-scale and larger scale requirements.
• Lower risk of attrition — early filtering for ADMET, solubility, etc., reduces risk of failing in later stages.
• Competitive differentiation — for CROs, academic labs or small biotech: having access to high-quality, diverse, drug-like libraries gives advantage in identifying novel chemical matter.
By working together, we can rapidly expand the map of nature’s chemistry
and tackle
pressing challenges across human and planetary health.
If this mission resonates,
we’d love to connect.